Form 8-K · Current report
Verisk Analytics 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0001442145
- Accession no.
- 0000950103-26-016441
Summary
Verisk Analytics said it will proceed in accordance with a Delaware Supreme Court order affirming a Delaware Chancery Court judgment concerning its transaction with ExactLogix, Inc., which does business as AccuLynx.com. Verisk said the transaction remains subject to customary closing conditions and FTC review and that completion is not guaranteed.
Key points
- Verisk issued a press release on October 23, 2026, in response to the Delaware Supreme Court order regarding the AccuLynx transaction.
- The Delaware Supreme Court order affirmed the judgment of the Delaware Chancery Court.
- The transaction remains subject to customary closing conditions and FTC review, and Verisk said there is no guarantee it will be completed.
- The merger agreement involves Verisk, Lenny Merger Sub, Inc., ExactLogix, Inc. d/b/a AccuLynx.com, and Richard Spanton, Jr. as representative of ExactLogix equityholders.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01. Other Events. On October 23, 2026, Verisk Analytics, Inc., a Delaware corporation (the “Company”), issued a press release in response to the Delaware Supreme Court order relating to the transactions contemplated by the Agreement and Plan of Merger (as it may be amended, restated, supplemented or otherwise modified from time to time) by and among the Company, Lenny Merger Sub, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company, ExactLogix, Inc., a Delaware corporation d/b/a AccuLynx.com (“ExactLogix”), and Richard Spanton, Jr., an individual, solely in his capacity as representative of the equityholders of ExactLogix thereunder. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.